Looking for Ribociclib found 6 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Ribociclib
(Kisqali®)
|
Malignant disease and immunosuppression - Breast cancer - 08.03.04.01
|
| |
Links Link to Drug Section  Link to document |
|
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
|
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
|
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (08.03.04.01)
|
|
NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (08.03.04.01)
|
|
|
